United States · Platforms & data · The Motley Fool

Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?

Published by The Motley Fool · United States 2 h ago

Eli Lilly's revenue nearly doubled over two years while Bristol Myers Squibb remained relatively flat, widening the gap between these two pharma giants.

Read the full article on The Motley Fool Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.fool.com)

Also worth reading

MarketBeat

Satellogic Targets Daily Global Intelligence With Merlin Satellite Constellation

Seeking Alpha

Fusion Fuel Green deal cuts QIND’s Al Shola Gas payments due to $7M

MarketWatch

Markets are pricing in long-term AI winners. This veteran investor says history proves customers win more than innovators.

Benzinga

Best Tech Stocks Right Now

Investing.com

Cantor Fitzgerald reiterates Texas Instruments stock neutral rating

Yahoo Finance